Skip to main content

CORRECTION article

Front. Oncol., 23 October 2023
Sec. Cancer Genetics

Corrigendum: A novel BRCA1 splicing variant detected in an early onset triple-negative breast cancer patient additionally carrying a pathogenic variant in ATM: a case report

  • 1Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
  • 2Department of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy

A Corrigendum on
A novel BRCA1 splicing variant detected in an early onset triple-negative breast cancer patient additionally carrying a pathogenic variant in ATM: a case report

by Colombo M, Mondini P, Minenza E, Foglia C, Mosconi A, Molica C, Pistola L, Ludovini V and Radice P (2023) Front. Oncol. 13:1102184. doi: 10.3389/fonc.2023.1102184

In the published article, the investigated BRCA1 variant was incorrectly reported as c.5406+6T>C. The correct annotation of the variant is c.5406+6T>G.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: BRCA1, ATM, double heterozygote, spliceogenic variant, case report

Citation: Colombo M, Mondini P, Minenza E, Foglia C, Mosconi A, Molica C, Pistola L, Ludovini V and Radice P (2023) Corrigendum: A novel BRCA1 splicing variant detected in an early onset triple-negative breast cancer patient additionally carrying a pathogenic variant in ATM: a case report. Front. Oncol. 13:1306238. doi: 10.3389/fonc.2023.1306238

Received: 03 October 2023; Accepted: 05 October 2023;
Published: 23 October 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Colombo, Mondini, Minenza, Foglia, Mosconi, Molica, Pistola, Ludovini and Radice. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Mara Colombo, mara.colombo@istitutotumori.mi.it

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.